Rostec transferred 100% of its shares in the manufacturer of immunobiological drugs to Natsimbio


Natsimbio, the holding of the Rostec State Corporation, has become the owner of 100% of the shares in RPA “Microgen” (the largest manufacturer of immunobiological drugs in Russia). This is reported by Rostec’s press service.

The facilities of Microgen currently produce 20 different vaccines for the prevention of 15 infectious diseases. 17 of these drugs are supplied to the Russian regions under contracts with the Ministry of Health of the Russian Federation to implement the National Calendar of Preventive Vaccinations (NCPV).

As part of the development of Microgen, the holding intends to increase production at the company’s branches in the Russian regions, as well as to create technological capacity and develop new medicines. It is planned to implement a large-scale investment program in Microgen, an important part of which will be the creation of a new production of vaccines and blood plasma preparations at the Perm enterprise.

“The transfer of the stake has been fully completed, and Microgen is now a part of Natsimbio. This is an important step towards creating a strong player in the Russian pharmaceutical market that can ensure the independence of the Russian Federation, which will produce its own strategically important biological drugs. We expect that the integration will give the company an additional impetus, which will allow us to create and produce medicines that meet all modern requirements,” said Andrey Zagorsky, General Director of the Natsimbio Holding.

Rostec State Corporation previously became the owner of a 26% stake in the Russian Pharmaceutical Company (RFC), the country’s largest manufacturer of alcohol-containing pharmaceutical substances and antiseptics, including those in the list of VED.